CD7‐directed chimeric antigen receptor T‐cell (CAR‐T) therapy is an emerging treatment option for refractory/relapsed T‐ALL/LBL, with CR rates exceeding 80% and even reaching 95% [47, 48]. The gene discussed is CD7; the disease is acute lymphoblastic leukemia.